8-K: Chemed Corp Q2 2026 Results: VITAS Drives Guidance Increase

Chemed Corporation reported strong second-quarter 2026 financial results, with revenue up 8.8% and EPS soaring 43.7%, primarily driven by outperformance in its VITAS Healthcare segment, leading to an increase in full-year guidance.

Summary

• Chemed Corporation announced its second-quarter 2026 financial results, showing a consolidated revenue increase of 8.8% to $673.3 million.
• GAAP Diluted Earnings-per-Share (EPS) rose significantly by 43.7% to $5.13, while Adjusted Diluted EPS increased by 41.9% to $6.06.
• The VITAS Healthcare segment experienced an 11.9% revenue increase to $443.3 million, with Average Daily Census (ADC) up 6.1% and admissions up 9.0%.
• VITAS' Net Income, excluding discrete items, grew by 60.5% to $61.3 million, and Adjusted EBITDA (excluding Medicare Cap) increased by 20.6% to $80.6 million.
• The Roto-Rooter segment reported a 3.3% revenue increase to $229.9 million, with Net Income and Adjusted EBITDA remaining essentially flat.
• Full-year 2026 EPS guidance was raised to a range of $25.00 to $25.75, up from $24.00 to $24.75, reflecting VITAS' improved performance.
• As of June 30, 2026, Chemed had $40.2 million in cash and cash equivalents and $140.0 million in long-term debt.
• The company repurchased approximately 1.52 million shares of its stock over the trailing 12 months, reducing outstanding shares by about 10.5%.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a positive report, driven by strong outperformance in the VITAS segment and a significant increase in full-year guidance, outweighing the flat performance in Roto-Rooter.

Positives

• Consolidated revenue increased by 8.8% to $673.3 million for the quarter.
• GAAP Diluted EPS surged by 43.7% to $5.13.
• Adjusted Diluted EPS grew by 41.9% to $6.06.
• VITAS segment revenue increased by 11.9% to $443.3 million.
• VITAS segment Net Income (excluding discrete items) increased by 60.5% to $61.3 million.
• VITAS segment Adjusted EBITDA (excluding Medicare Cap) increased by 20.6% to $80.6 million.
• VITAS segment Adjusted EBITDA margin improved by 196 basis points to 18.2%.
• Roto-Rooter segment revenue increased by 3.3% to $229.9 million.

Negatives

• Roto-Rooter segment Net Income remained essentially flat.
• Roto-Rooter segment Adjusted EBITDA remained essentially flat.
• Roto-Rooter segment Adjusted EBITDA margin declined by 77 basis points to 21.1%.
• VITAS experienced a negative impact on revenue growth of 115 basis points due to acuity mix shift.
• VITAS recorded a $0.5 million Medicare Cap billing limitation in Q2 2026, compared to $16.4 million in Q2 2025.
• Four VITAS Medicare provider numbers have a Medicare Cap billing limitation totaling $7.0 million.

Risks

• The impact of laws and regulations on Chemed's operations, including Medicare Cap and Medicare reimbursement rates.
• Chemed's estimates of the effect of Medicare Cap on VITAS revenues and future prospects.
• Chemed's expectations regarding VITAS patient mix.
• Chemed's expectations regarding demand for Roto-Rooter's services.
• Potential for future Medicare Cap billing limitations impacting VITAS' financial performance.
• Acuity mix shift negatively impacting VITAS revenue growth.

Future Outlook

Full-year 2026 earnings per diluted share (excluding certain items) are now estimated to be in the range of $25.00 to $25.75, an increase from the previous guidance of $24.00 to $24.75. This revision is primarily due to the materially improved performance of VITAS. Roto-Rooter's full-year guidance remains unchanged with anticipated revenue growth of 3.0% to 3.5% and estimated adjusted EBITDA margin of 21.5% to 22.5%.

Management Comments

• VITAS initiatives to return to a normal growth pattern after managing the 2025 Medicare Cap issue progressed more quickly than originally anticipated and continue to provide higher than expected growth in the business.
• Roto-Rooter performed in-line with our expectations and therefore, full year guidance for the segment remains unchanged.

Industry Context

StockSavvy.ai notes that Chemed's strong performance in the hospice care sector, particularly VITAS, highlights the growing demand for end-of-life services. The company's ability to navigate regulatory challenges like the Medicare Cap and translate operational improvements into increased profitability is a key differentiator in the healthcare services industry. The stable performance of Roto-Rooter in a competitive market also demonstrates resilience.

Comparison to Industry Standards

• VITAS' 11.9% revenue growth and 20.6% Adjusted EBITDA growth in the hospice sector outpace many industry averages, which typically see single-digit growth.
• Roto-Rooter's 3.3% revenue growth is in line with stable, mature service industries, but its flat EBITDA suggests pressure on margins, a common theme in competitive service markets.
• Chemed's overall EPS growth of 43.7% is significantly higher than the average for diversified healthcare companies.

Legal Proceedings

• The filing mentions 'costs related to litigation' as an item excluded from full-year guidance, indicating ongoing legal matters.

Stakeholder Impact

• Shareholders: Positive impact due to increased EPS, raised full-year guidance, and significant share repurchases.
• Employees: Continued growth in VITAS may lead to increased employment opportunities in hospice care.
• Customers: Continued service provision by VITAS and Roto-Rooter.
• Creditors: Improved financial performance and a new credit agreement provide a stable outlook.

Next Steps

• Host conference call and webcast on July 29, 2026, to discuss quarterly results and provide business updates.
• Continue to monitor VITAS' performance and Medicare Cap implications.
• Execute on Roto-Rooter's growth strategies.

Key Dates

Recommendation

The company delivered strong results and increased guidance, primarily driven by VITAS' outperformance. However, Roto-Rooter's flat performance and the inherent risks in the healthcare sector (e.g., regulatory changes, acuity mix shifts) warrant a cautious approach. While positive, the results are largely expected given the prior commentary on VITAS' recovery, suggesting a 'hold' rating until further sustained growth or clearer industry tailwinds emerge.

Keywords

Chemed Corporation, VITAS Healthcare, Roto-Rooter, Hospice Care, Plumbing Services, End-of-Life Care, Healthcare, Financial Results